Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Respiratory syncytial virus

Recent news which mentions Respiratory syncytial virus

Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
Tags Biotechnology Business News Merck & Co Inc
From CNBC.com News
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
Tags Biotechnology Business News US: News
From CNBC.com News
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Tags GSK plc Business Health & Science
From CNBC.com News
RSV vaccine from GSK shows potential to protect adults 50 to 59
Tags Health & Science Social issues Business
From CNBC.com News
CDC advisors recommend Pfizer maternal RSV vaccine to protect infants
Tags Health & Science Social issues Business
From CNBC.com News
FDA approves Pfizer maternal RSV vaccine for infants
Tags Respiratory syncytial virus Breaking news Biotech and Pharmaceuticals
From CNBC.com News
GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine
Tags Biotech and Pharmaceuticals Respiratory syncytial virus Breaking news
From CNBC.com News
GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
Tags Business Health & Science GSK plc
From CNBC.com News
CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older
Tags Biotech and Pharmaceuticals Respiratory syncytial virus Business
From CNBC.com News
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says
Tags Business News Biotechnology US: News
From CNBC.com News
CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60
Tags Business Social issues Health & Science
From CNBC.com News
GSK says RSV vaccine for older adults provides protection over two seasons
Tags Biotechnology Business News US: News
From CNBC.com News
Pfizer RSV vaccine for older adults is only slightly less effective after 18 months
Tags Biotech and Pharmaceuticals Breaking news Respiratory syncytial virus
From CNBC.com News
FDA approves Pfizer RSV vaccine for older adults
Tags Pfizer Inc Health care industry Breaking News: Business
From CNBC.com News
Here’s what Pfizer and Moderna say is next for their Covid vaccines
Tags Biotech and Pharmaceuticals Respiratory syncytial virus Moderna Inc
From CNBC.com News
FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns
Tags Breaking News: Business US: News Business News
From CNBC.com News
Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say
Tags Health care industry Vaccinations Companies
From CNBC.com News
FDA approves GSK's RSV vaccine for older adults, world's first shot against virus
Tags Biotechnology Drug approvals COVID/19
From CNBC.com News
FDA says Guillain-Barre syndrome is possible risk of Pfizer's RSV vaccine for older adults
Tags Breaking News: Business US: News Biotechnology
From CNBC.com News
Moderna, Pfizer's new race: The RSV vaccine FDA approval process
Tags Respiratory syncytial virus Moderna Inc CNBC Disruptor 50
From CNBC.com News
A nutritionist shares the best snacks to bring on a plane to boost your immune system
Tickers LIFE
Tags Respiratory syncytial virus Holidays Travel safety
From CNBC.com News
Why flu season is so bad this year
Tickers LIFE
Tags Pharmaceuticals Health care industry Children
From CNBC.com News
Pfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company's data shows
Tags Epidemics Health & Science Business
From CNBC.com News
Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
Tickers AZN AZNCF SNY
Tags AZN News Market News
From Benzinga
Pfizer's RSV Vaccine Candidate Receives FDA Breakthrough Therapy Tag For Prevention of RSV In Older Adults
Tickers PFE
Tags PFE Briefs General
From Benzinga
Johnson & Johnson Posts Additional RSV Vaccine Data
Tickers JNJ
Tags Biotech News JNJ
From Benzinga
J&J's RSV Vaccine Candidate Shows 80% Efficacy In Older Adults
Tickers JNJ
Tags REspiratory syncytial virus Health Care Briefs
From Benzinga
Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate In Older Patients
Tickers PFE
Tags Health Care REspiratory syncytial virus General
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.